Preparation for the 2023 pollen season Review article
Article Sidebar
Published:
Jan 5, 2023
Keywords:
pollen season, allergic rhinitis, antihistamines, intranasal glucocorticosteroids
Main Article Content
Abstract
The preparation for the pollen season of a patient allergic to plant pollen allergens involves both educating the patient, allowing the application of prophylactic principles to limit contact with the allergen, and recommending appropriate therapy based on symptomatic and anti-inflammatory medication. By knowing the pollen seasons of allergenic trees, grasses and weeds and having access to current information on pollen concentrations in the air during the pollen season, preventive measures can be taken to reduce the risk of increased allergy symptoms. The use of a therapeutic management algorithm in allergic rhinitis using modern antihistamines and intranasal glucocorticoids can control the symptoms of the disease. Allergen-specific immunotherapy is a causal treatment method to achieve tolerance to an allergy-causing agent and affect the natural course of the disease.
Downloads
Download data is not yet available.
Article Details
How to Cite
Samoliński , B., Krzych-Fałta, E., Lipiec , A., & Samoliński , K. (2023). Preparation for the 2023 pollen season. Alergoprofil, 18(4), 3-10. https://doi.org/10.24292/01.AP.184050123
Issue
Section
THERAPY
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Malkiewicz M, Drzeniecka-Osiadacz A, Krynicka J. The dynamics of the Corylus, Alnus, and Betula pollen seasons in the context of climate change (SW Poland). Sci Total Environ. 2016; 573: 740-50.
2. Rapiejko P. Alergeny pyłku roślin. Medical Education, Warszawa 2012.
3. Myszkowska D. Predicting tree pollen season start dates using thermal conditions. Aerobiologia. 2014; 30(3): 307-21.
4. Samoliński B, Raciborski F, Lipiec A et al. Epidemiologia chorób alergicznych w Polsce (ECAP). Pol J Allergol. 2014; 1: 10-8.
5. Samoliński B, Sybilski AJ, Raciborski F et al. Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol Pol. 2009; 63(4): 324-30.
6. Kubik-Komar A, Piotrowska-Weryszko K, Weryszko-Chmielewska E et al. A study on the spatial and temporal variability in airborne Betula pollen concentration in five cities in Poland using multivariate analyses. Sci Total Environ. 2019; 10(660): 1070-8.
7. Werner M, Guzikowski J, Kryza M et al. Extension of WRF-Chem for birch pollen modelling-a case study for Poland. Int J Biometeorol. 2021; 65(4): 513-26.
8. Puc M, Wolski T, Câmara Camacho I et al. Fluctuation of birch (Betula L.) pollen seasons in Poland. Acta Agrobot. 2015; 68(4): 303-13.
9. Grewling Ł, Jackowiak B, Nowak M et al. Variations and trends of birch pollen seasons during 15 years (1996–2010) in relation to weather conditions in Poznań (western Poland). Grana. 2012; 51(4): 280-92.
10. Lipiec A, Rapiejko P, Furmańczyk K et al. The dynamics of pollen seasons of the most allergenic plants – 15-year observations in Warsaw. Otolaryngol Pol. 2018; 72(6): 44-53.
11. Rapiejko P. Aerobiologia medyczna. Alerg Astma Immunol. 2006; 11(2): 76-82.
12. Dąbrowska-Zapart K, Chłopek K, Lipiec A et al Grass pollen season in selected cities of Poland in 2019. Alergoprofil. 2019; 15(3): 23-7.
13. Piotrowska-Weryszko K, Weryszko-Chmielewska E, Sulborska A et al. Comparison of Artemisia L. pollen concentrations and risk of development of allergy symptoms in different regions of Poland in 2020. Alergoprofil. 2020; 16(4): 27-33.
14. Nowak M, Szymańska A. Stężenie zarodników Alternaria w powietrzu Poznania w latach 2008–2011. Alergoprofil. 2012; 8(2): 19-22.
15. D’Amato G, Vitale C, Lanza M et al. Climate change, air pollution, and allergic respiratory diseases. Curr Opin Allergy Clin Immunol. 2016; 16(5): 434-40.
16. Ziemianin M, Waga J, Czarnobilska E et al. Changes in qualitative and quantitative traits of birch (Betula pendula) pollen allergenic proteins in relation to the pollution contamination. Environ Sci Pollut Res Int. 2021; 28(29): 39952-65.
17. Charakterystyka produktu leczniczego Bilaxten, 2,5 mg/ml, roztwór doustny (access: 28.11.2022).
18. ChPL Hitaxa (access: 28.11.2022).
19. ChPL Contrahist (access: 28.11.2022).
20. Sadowska-Woda I, Bieszczad-Bedrejczuk E. Spektrum działania farmakologicznego desloratadyny. Alerg Astma Immunol. 2010; 15(4): 189-96.
21. Aneks do charakterystyki produktu leczniczego. Desloratadine ratiopharm.
22. Rygalski M, Zawisza E. Atrybuty nowoczesnego leku przeciwhistaminowego. Lek w Polsce. 2015; 25(3): 20-5.
23.ChPL Lecetax (access: 2.02.2023).
24. ChPL Rupafin (access: 2.02.2022).
25. Corcostegui R, Labeaga L, Innerárity A et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs. 2006; 7: 219-31.
26. Brożek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.\ J Allergy Clin Immunol. 2010; 126: 466-76.
27. Bachert C, Kuna P, Sanquer F et al. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009; 64: 158-65.
28. Kuna P, Bachert C, Nowacki Z et al. Bilastine International Working Group Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double- blind, parallel-group study. Clin Exp Allergy. 2009; 39: 1338-47.
29. Horak F, Zieglmayer P, Zieglmayer R et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010; 59: 391-8. http://doi.org/10.1007/s00011-009-0117-4.
30. Pawliczak R. Bezpieczeństwo nowych leków przeciwhistaminowych. Terapia. 2012; 4: 60-6.
31. Rapiejko P, Lipiec A. Bilastyna w leczeniu alergicznego nieżytu nosa. Postep Derm. Alergol. 2014; XXXI(suppl 2): s16-27.
32. Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012; 16(14): 1999-2005.
33. FAES FARMA SA. Bilastine, Investigational Drug Brochure version 8.0, July 2007. FAES FARMA S.A . www.faes.es (access: 28.11.2022).
34. Schafer T, Schnoor M, Wagenmann M et al. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011; 49(3): 272-80.
35. Narbutt J. Leki przeciwhistaminowe II generacji w praktyce codziennej. Pediatr Med Rodz. 2012; 8(4): 351-9.
36. Panek M, Pietras T, Kuna P. Leki antyhistaminowe – kiedy i jak stosować w chorobach alergicznych. Terapia. 2014; 3(1): 23-9.
37. Ciebiada M, Ciebiada-Górska M, Górski P. Desloratadyna w leczeniu całorocznego alergicznego nieżytu nosa-wieloośrodkowe badanie w Polsce. Alerg Astma Immunol. 2002; 8(2): 101-5.
38. Brożek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 2010; 126: 466-76.
39. Samoliński B, Arcimowicz M. Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska, S1, Medycyna Praktyczna. 2013.
40. O`Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136(2): 197-201.
41. ChPL Momester (access: 28.11.2022).
42. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group. World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001; 108(5 suppl): S147-334.
43. Brozek JL, Bousquet J, Baena-Cagnani CE et al; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126(3): 466-76.
44. Bousquet J, Schünemann HJ, Samolinski B et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012; 130(5): 1049-62.
45. Bousquet JJ, Schünemann HJ, Togias A et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clin Transl Allergy. 2019; 9: 44. http://doi.org/10.1186/s13601-019-0279-2.
46. Bousquet J, Schünemann HJ, Togias A et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real- world evidence. J Allergy Clin Immunol. 2020; 145(1): 70-80.e3. http://doi.org/10.1016/j.jaci.2019.06.049.
47. Bousquet J, Hellings PW, Agache I et al; Mobile Airways Sentinel Network (MASK) Study Group. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2019; 143(3): 864-79. http://doi.org/10.1016/j.jaci.2018.08.049.
48. Bousquet J, Arnavielhe S, Bedbrook A. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018; 8: 45. http://doi.org/10.1186/s13601-018-0227-6.
49. Krzych-Fałta E, Samoliński B, Wojas O. Mometazon w leczeniu alergicznego nieżytu nosa. Świat Medycyny i Farmacji. 2020; 62-8.
50. Emeryk A, Janeczek K. Furoinian mometazonu – najlepszy glikokortykosteroid donosowy? Świat Medycyny i Farmacji. 2021; 7(240): 14-8.
51. Pyzia Ł, Pyzia S, Krzewicka-Romaniuk E et al. Furonian mometazonu w leczeniu alergicznego nieżytu nosa. Świat Medycyny i Farmacji. 2022: 64.
52. Sousa-Pinto B, Schünemann HJ, Sá-Sousa A et al. Comparison of rhinitis treatments using real-world MASK-air® data in a multivariable mixed-effects model and Minimal Clinically Important Difference (MCID). Allergy. 2022; 77(10): 3002-14. http://doi.org/10.1111/all.15371.
53. Bousquet J, Pfaar O, Togias A et al. 2019 ARIA Care pathways for allergen immunotherapy Allergy. 2019; 74(11): 2087-102. http://doi.org/10.1111/all.13805.
54. Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4): 950-8. http://doi.org/10.1016/j.jaci.2017.03.050.
55. Bousquet J, Pfaar O, Agache I et al. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. Clin Transl Allergy. 2021; 11(4): e12014. http://doi.org/10.1002/clt2.12014.
56. Roberts G, Pfaar O, Akdis CA et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018; 73(4): 765-98.
57. Alvaro-Lozano M, Akdis CA, Akdis M et al. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020; 31(suppl 25): 1-101.
2. Rapiejko P. Alergeny pyłku roślin. Medical Education, Warszawa 2012.
3. Myszkowska D. Predicting tree pollen season start dates using thermal conditions. Aerobiologia. 2014; 30(3): 307-21.
4. Samoliński B, Raciborski F, Lipiec A et al. Epidemiologia chorób alergicznych w Polsce (ECAP). Pol J Allergol. 2014; 1: 10-8.
5. Samoliński B, Sybilski AJ, Raciborski F et al. Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol Pol. 2009; 63(4): 324-30.
6. Kubik-Komar A, Piotrowska-Weryszko K, Weryszko-Chmielewska E et al. A study on the spatial and temporal variability in airborne Betula pollen concentration in five cities in Poland using multivariate analyses. Sci Total Environ. 2019; 10(660): 1070-8.
7. Werner M, Guzikowski J, Kryza M et al. Extension of WRF-Chem for birch pollen modelling-a case study for Poland. Int J Biometeorol. 2021; 65(4): 513-26.
8. Puc M, Wolski T, Câmara Camacho I et al. Fluctuation of birch (Betula L.) pollen seasons in Poland. Acta Agrobot. 2015; 68(4): 303-13.
9. Grewling Ł, Jackowiak B, Nowak M et al. Variations and trends of birch pollen seasons during 15 years (1996–2010) in relation to weather conditions in Poznań (western Poland). Grana. 2012; 51(4): 280-92.
10. Lipiec A, Rapiejko P, Furmańczyk K et al. The dynamics of pollen seasons of the most allergenic plants – 15-year observations in Warsaw. Otolaryngol Pol. 2018; 72(6): 44-53.
11. Rapiejko P. Aerobiologia medyczna. Alerg Astma Immunol. 2006; 11(2): 76-82.
12. Dąbrowska-Zapart K, Chłopek K, Lipiec A et al Grass pollen season in selected cities of Poland in 2019. Alergoprofil. 2019; 15(3): 23-7.
13. Piotrowska-Weryszko K, Weryszko-Chmielewska E, Sulborska A et al. Comparison of Artemisia L. pollen concentrations and risk of development of allergy symptoms in different regions of Poland in 2020. Alergoprofil. 2020; 16(4): 27-33.
14. Nowak M, Szymańska A. Stężenie zarodników Alternaria w powietrzu Poznania w latach 2008–2011. Alergoprofil. 2012; 8(2): 19-22.
15. D’Amato G, Vitale C, Lanza M et al. Climate change, air pollution, and allergic respiratory diseases. Curr Opin Allergy Clin Immunol. 2016; 16(5): 434-40.
16. Ziemianin M, Waga J, Czarnobilska E et al. Changes in qualitative and quantitative traits of birch (Betula pendula) pollen allergenic proteins in relation to the pollution contamination. Environ Sci Pollut Res Int. 2021; 28(29): 39952-65.
17. Charakterystyka produktu leczniczego Bilaxten, 2,5 mg/ml, roztwór doustny (access: 28.11.2022).
18. ChPL Hitaxa (access: 28.11.2022).
19. ChPL Contrahist (access: 28.11.2022).
20. Sadowska-Woda I, Bieszczad-Bedrejczuk E. Spektrum działania farmakologicznego desloratadyny. Alerg Astma Immunol. 2010; 15(4): 189-96.
21. Aneks do charakterystyki produktu leczniczego. Desloratadine ratiopharm.
22. Rygalski M, Zawisza E. Atrybuty nowoczesnego leku przeciwhistaminowego. Lek w Polsce. 2015; 25(3): 20-5.
23.ChPL Lecetax (access: 2.02.2023).
24. ChPL Rupafin (access: 2.02.2022).
25. Corcostegui R, Labeaga L, Innerárity A et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs. 2006; 7: 219-31.
26. Brożek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision.\ J Allergy Clin Immunol. 2010; 126: 466-76.
27. Bachert C, Kuna P, Sanquer F et al. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009; 64: 158-65.
28. Kuna P, Bachert C, Nowacki Z et al. Bilastine International Working Group Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double- blind, parallel-group study. Clin Exp Allergy. 2009; 39: 1338-47.
29. Horak F, Zieglmayer P, Zieglmayer R et al. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010; 59: 391-8. http://doi.org/10.1007/s00011-009-0117-4.
30. Pawliczak R. Bezpieczeństwo nowych leków przeciwhistaminowych. Terapia. 2012; 4: 60-6.
31. Rapiejko P, Lipiec A. Bilastyna w leczeniu alergicznego nieżytu nosa. Postep Derm. Alergol. 2014; XXXI(suppl 2): s16-27.
32. Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012; 16(14): 1999-2005.
33. FAES FARMA SA. Bilastine, Investigational Drug Brochure version 8.0, July 2007. FAES FARMA S.A . www.faes.es (access: 28.11.2022).
34. Schafer T, Schnoor M, Wagenmann M et al. Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. Rhinology. 2011; 49(3): 272-80.
35. Narbutt J. Leki przeciwhistaminowe II generacji w praktyce codziennej. Pediatr Med Rodz. 2012; 8(4): 351-9.
36. Panek M, Pietras T, Kuna P. Leki antyhistaminowe – kiedy i jak stosować w chorobach alergicznych. Terapia. 2014; 3(1): 23-9.
37. Ciebiada M, Ciebiada-Górska M, Górski P. Desloratadyna w leczeniu całorocznego alergicznego nieżytu nosa-wieloośrodkowe badanie w Polsce. Alerg Astma Immunol. 2002; 8(2): 101-5.
38. Brożek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 2010; 126: 466-76.
39. Samoliński B, Arcimowicz M. Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska, S1, Medycyna Praktyczna. 2013.
40. O`Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997; 136(2): 197-201.
41. ChPL Momester (access: 28.11.2022).
42. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group. World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001; 108(5 suppl): S147-334.
43. Brozek JL, Bousquet J, Baena-Cagnani CE et al; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126(3): 466-76.
44. Bousquet J, Schünemann HJ, Samolinski B et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012; 130(5): 1049-62.
45. Bousquet JJ, Schünemann HJ, Togias A et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clin Transl Allergy. 2019; 9: 44. http://doi.org/10.1186/s13601-019-0279-2.
46. Bousquet J, Schünemann HJ, Togias A et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real- world evidence. J Allergy Clin Immunol. 2020; 145(1): 70-80.e3. http://doi.org/10.1016/j.jaci.2019.06.049.
47. Bousquet J, Hellings PW, Agache I et al; Mobile Airways Sentinel Network (MASK) Study Group. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2019; 143(3): 864-79. http://doi.org/10.1016/j.jaci.2018.08.049.
48. Bousquet J, Arnavielhe S, Bedbrook A. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018; 8: 45. http://doi.org/10.1186/s13601-018-0227-6.
49. Krzych-Fałta E, Samoliński B, Wojas O. Mometazon w leczeniu alergicznego nieżytu nosa. Świat Medycyny i Farmacji. 2020; 62-8.
50. Emeryk A, Janeczek K. Furoinian mometazonu – najlepszy glikokortykosteroid donosowy? Świat Medycyny i Farmacji. 2021; 7(240): 14-8.
51. Pyzia Ł, Pyzia S, Krzewicka-Romaniuk E et al. Furonian mometazonu w leczeniu alergicznego nieżytu nosa. Świat Medycyny i Farmacji. 2022: 64.
52. Sousa-Pinto B, Schünemann HJ, Sá-Sousa A et al. Comparison of rhinitis treatments using real-world MASK-air® data in a multivariable mixed-effects model and Minimal Clinically Important Difference (MCID). Allergy. 2022; 77(10): 3002-14. http://doi.org/10.1111/all.15371.
53. Bousquet J, Pfaar O, Togias A et al. 2019 ARIA Care pathways for allergen immunotherapy Allergy. 2019; 74(11): 2087-102. http://doi.org/10.1111/all.13805.
54. Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4): 950-8. http://doi.org/10.1016/j.jaci.2017.03.050.
55. Bousquet J, Pfaar O, Agache I et al. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. Clin Transl Allergy. 2021; 11(4): e12014. http://doi.org/10.1002/clt2.12014.
56. Roberts G, Pfaar O, Akdis CA et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018; 73(4): 765-98.
57. Alvaro-Lozano M, Akdis CA, Akdis M et al. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020; 31(suppl 25): 1-101.